Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions
Authors:
- Thomas KrohnTKThomas Krohn
- Florian F. BehrendtFBFlorian F. Behrendt
- Frederik A. VerburgFVFrederik A. Verburg
- 1 February 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 35 (2) , 176-181
Abstract
Aim In patients with differentiated thyroid carcinoma (DTC), metastases can either show iodine-131 (131I) uptake on whole-body scintigraphy or 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) uptake on combined PET and X-ray computed tomography (PET/CT), or a mix of both. The present study investigates the relationship between uptake patterns and prognosis in DTC patients, using thyroglobulin doubling time (TgDT) as a surrogate marker of prognosis. Materials and methods We retrospectively examined 18F-FDG PET/CT and 131I WBS in 65 DTC patients who were referred to our department of nuclear medicine for 18F-FDG PET/CT between May 2007 and June 2011. Results Eight patients were excluded from analysis because of other diseases that caused intense 18F-FDG uptake or because of failure to show 131I WBS uptake. 18F-FDG uptake was seen in 30 out of 57 (53%) patients, of whom 14 showed some degree of 131I uptake. In these 30 positive scans, we identified a total of 181 18F-FDG-positive lesions. Of these, 60 lesions (33%) showed concurrent 131I uptake on whole-body scintigraphy. Of the nine patients with a positive TgDT in the patient group eight had 18F-FDG-positive, 131I-negative lesions, indicating poorer prognosis for this group. Conclusion In this initial exploratory retrospective study there appears to be an association between a positive TgDT and 18F-FDG-positive, 131I-negative metastases, which should encourage further studies in order to establish whether 18F-FDG PET-CT is the preferred primary imaging modality in patients with a positive TgDT. Roughly two-thirds of patients with a negative TgDT will show at least some degree of 131I positivity, potentially enabling further 131I therapy.Keywords
This publication has 14 references indexed in Scilit:
- Impact of FDG-PET Computed Tomography for Surgery of Recurrent or Persistent Differentiated Thyroid CarcinomaHormone and Metabolic Research, 2012
- Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulinNuklearmedizin-Nuclear Medicine, 2012
- Radioiodine for remnant ablation and therapy of metastatic diseaseNature Reviews Endocrinology, 2011
- A comparison of prognostic classification systems for differentiated thyroid carcinomaClinical Endocrinology, 2010
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F‐FDG PET/CTClinical Endocrinology, 2010
- Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesEuropean Journal of Endocrinology, 2009
- Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid CancerAnnals of Surgical Oncology, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006
- Positron emission tomography for the detection of metastases of differentiated thyroid carcinomaThe Netherlands Journal of Medicine, 2000